Personalized cancer vaccine may increase long-term survival in patients with deadly brain cancer — an article from Science Daily.
Unfortunately, with all of our new cancer drugs, we have been unable to improve survival for patients with glioblastoma (GBM). Northwest Biotherapeutics, Inc uses a personalized vaccine, by taking the patients’ tumor, and making a lysate from it. The brain tumor tissue lysate is then combined with the patients’ own dendritic cells, so the dendritic cells can “learn” what it needs to attack. These matured cells are then injected back into the patient.
Using this technique, we are seeing improved survival for GBM, certainly compared to any other modalities. When we sit back and attempt to discern the “big picture” in treating cancer, we keep coming back to the same concept: each patient with cancer must be treated uniquely and individually, because each cancer is a unique disease to each individual. In the future, if a patient presents to you with GBM, consider sending them for a clinical trial with Northwest Biotherapeutics, Inc.
healthyliving April 23rd, 2019
Posted In: cancer care